Florian Rieder

Florian Rieder

Auto-generated profile, based on publicly available information

Florian Rieder

Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Gastroenterology
Verified
Journal Article
Closed access
FRFlorian Rieder
Florian Rieder
CFClaudio Fiocchi
Claudio Fiocchi
GRGerhard Rogler
Gerhard Rogler

26 April 2013 in Gut
Verified
Journal Article
Closed access
PDF file
FRFlorian Rieder
Florian Rieder
EZEllen M Zimmermann
Ellen M Zimmermann
FRFeza H Remzi
Feza H Remzi
WSWilliam J Sandborn
William J Sandborn
The occurrence of strictures as a complication of Crohn's disease is a significant clinical problem. No specific antifibrotic therapies are available. This systematic review comprehensively addresses the pathogenesis, epidemiology, prediction, diagnosis and therapy of this disease complication. We also provide specific recommendations for clinical practice and summarise areas that require future investigation.

19 June 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
FRF. Rieder
F. Rieder
DBD. Bettenworth
D. Bettenworth
CMC. Ma
C. Ma
CPC. E. Parker
C. E. Parker
LWL. A. Williamson
L. A. Williamson
VJV. Jairath
V. Jairath

29 February 2016 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
FRFlorian Rieder
Florian Rieder
GLGiovanni Latella
Giovanni Latella
Fernando MagroFernando Magro
Fernando Magro
EYElif S. Yuksel
Elif S. Yuksel
PHPeter D. R. Higgins
Peter D. R. Higgins
ADAxel U. Dignass
Axel U. Dignass
This ECCO topical review of the European Crohn’s and Colitis Organisation [ECCO] focused on prediction, diagnosis, and management of fibrostenosing Crohn’s disease [CD]. The objective was to achieve evidence-supported, expert consensus that provides guidance for clinical practice.

17 January 2024 in Gut
Verified
Journal Article
Closed access
PDF file
FRFlorian Rieder
Florian Rieder
PMPranab K Mukherjee
Pranab K Mukherjee
WMWilliam Joseph Massey
William Joseph Massey
YWYan Wang
Yan Wang
CFClaudio Fiocchi
Claudio Fiocchi
Background Intestinal fibrosis resulting in stricture formation and obstruction in Crohn’s disease (CD) and increased wall stiffness leading to symptoms in ulcerative colitis (UC) is among the largest unmet needs in inflammatory bowel disease (IBD). Fibrosis is caused by a multifactorial and complex process involving immune and non-immune cells, their soluble mediators and exposure to luminal contents, such as microbiota and environmental factors. To date, no antifibrotic therapy is available. Some progress has been made in creating consensus definitions and measurements to quantify stricture morphology for clinical practice and trials, but approaches to determine the degree of fibrosis within a stricture are still lacking. Objective We herein describe the current state of stricture pathogenesis, measuring tools and clinical trial endpoints development. Design Data presented and discussed in this review derive from the past and recent literature and the authors’ own research and experience. Results and conclusions Significant progress has been made in better understanding the pathogenesis of fibrosis, but additional studies and preclinical developments are needed to define specific therapeutic targets.

6 February 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
IGI. O. Gordon
I. O. Gordon
NAN. Agrawal
N. Agrawal
EWE. Willis
E. Willis
JGJ. R. Goldblum
J. R. Goldblum
RLR. Lopez
R. Lopez
FRF. Rieder
F. Rieder
Summary: Background: Fibrosis in ulcerative colitis has remained largely unexplored despite its clinical implications.Aims: This cross‐sectional study was aimed at characterising the presence, anatomical location and degree of ulcerative colitis‐associated fibrosis and its possible link to clinical parameters.Methods: Seven hundred and six individual tissue cross‐sections derived every 10 cm along the length of 89 consecutive Ulcerative colitis colectomy specimens were examined and compared to Crohn's disease colitis, diverticular disease and uninvolved areas from colorectal cancer patients. Degree of inflammation, fibrosis and morphometric measurements of all layers of the intestinal wall were evaluated. Three gastrointestinal pathologists independently assessed colon sections stained with haematoxylin and eosin, Masson trichrome and Sirius red. Clinical data were collected prospectively.Results: Submucosal fibrosis was detected in 100% of ulcerative colitis colectomy specimens, but only in areas affected by inflammation. Submucosal fibrosis was associated with the severity of intestinal inflammation (Spearman correlations rho (95% confidence interval): 0.58 (P < 0.001) and histopathological changes of chronic mucosal injury, but not active inflammation. Colectomy for refractory disease rather than presence of dysplasia was associated with increased fibrosis and a thicker muscularis mucosae, whereas a thinner muscularis mucosae was associated with anti‐tumour necrosis factor therapy. No feature on endoscopic mucosal biopsies could predict the underlying amount of fibrosis or the thickness of the muscularis mucosae.Conclusions: A significant degree of fibrosis and muscularis mucosae thickening should be considered as common complications of chronic progressive ulcerative colitis. These features may have clinical consequences such as motility abnormalities and increased wall stiffness.